Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Care Plans, Education Improve Long-term Quality of Life

June 17, 2023
By Julie M. Vose, MD, MBA
Publication
Article
OncologyONCOLOGY Vol 37, Issue 6
Volume 37
Issue 6
Pages: 233

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the optimal ways to manage short- and long-term toxicities associated with cancer.

With 1 in 3 individuals receiving a cancer diagnosis sometime during their lifetime, we all are likely to experience cancer ourselves or to have a relative or close friend with cancer. Fortunately, there have been vast improvements in treatments and care for patients with cancer. But with those successful treatments often come short- and long-term toxicities that must be managed.

In 2006, the Institute of Medicine and the National Academies established a committee to examine the range of medical and psychosocial issues faced by cancer survivors needed to improve their health care and quality of life.1 The committee set out 10 recommendations that fit into 4 broad categories: prevention, surveillance, intervention, and coordination.1 One big part of the recommendations was that each patient who had received cancer therapy should receive a survivorship care plan written by the team providing the cancer care. These plans should be developed systematically and on evidence-based clinical practice guidelines, the committee noted. Many of these plans have been developed as a shared-care model in which specialists work collaboratively with primary care providers. This model is likely the most successful because much of the cancer survivor’s health care is provided by their primary care network.

In addition to evaluations for cancer recurrence, services are needed for cancer screenings and evaluation of secondary effects such as organ dysfunction or secondary malignancies. Educating patients on primary and secondary prevention services, such as smoking cessation or regular cancer screening tests, is an important part of cancer survivorship. Cancer survivors also should receive additional lifestyle education such as how to maintain a healthy weight or increase activity. Some vital issues that are difficult to address include the need for services from psychologists or social workers. Even though the American Disabilities Act, has offered cancer survivors some protections from discriminatory practices, there are still many cases of health-related discrimination. Survivorship is an essential part of cancer care and benefits should be available based on evidence-based medicine.

The written survivorship care plan that is done at the end of active treatment for a patient with cancer does not guarantee a smooth transition or adequate education. It is an outline or road map for the patient, family, and primary care physician to follow. It should be a short, concise document that contains relevant information but does not overwhelm the patient or family. A specialty team trained to deliver the survivorship care plan is particularly beneficial in assisting patients with the transition.

A follow-up national cancer policy forum workshop in 2017 examined the implementation of the 2006 recommendations.2 Although many of the original recommendations have been implemented, some are less universal, such as protections from health-related discriminatory practices.2 Investing in research to improve cancer survivorship also was called out in the recommendations, particularly research on mechanisms of the late effects, prevalence of the risk of late effects, and interventions to improve the quality of life of all cancer survivors, their families, and caregivers. As a community of hematologists/oncologists, we owe it to our patients to not only improve our anticancer therapies but also to decrease the short- and long-term effects of the therapies we recommend for our patients.

References

  1. Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press; 2005.
  2. Kline RM, Arora NK, Bradley CJ, et al. Long-term survivorship care after cancer treatment - summary of a 2017 National Cancer Policy Forum workshop. J Natl Cancer Inst. 2018;110(12):1300- 1310. doi:10.1093/jnci/djy176
Download Issue PDFDownload PDF
Articles in this issue

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Squamous Cell Carcinoma of the Kidney: A Large Case Series
Squamous Cell Carcinoma of the Kidney: A Large Case Series
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Researchers Seek More Treatment Options for Gastrointestinal Cancer
Researchers Seek More Treatment Options for Gastrointestinal Cancer
Care Plans, Education Improve Long-term Quality of Life
Care Plans, Education Improve Long-term Quality of Life
Recent Videos
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
A Strong Network of Clinicians Makes Cancer Care More Efficient
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Fostering Multidisciplinary Care May Reduce Oncologist Workplace Burnout
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Communication Between Leadership and Clinicians Improves Cancer Care
What Does It Mean to Experience Workplace Burnout as an Oncologist?
What Does It Mean to Experience Workplace Burnout as an Oncologist?
Oncologists Need to Rely Upon NPs, PAs, and NPPs to Overcome Workforce Problems
Oncologists Need to Rely Upon NPs, PAs, and NPPs to Overcome Workforce Problems
Societal Changes, COVID-19 Among Causes of Oncologist Burnout
Societal Changes, COVID-19 Among Causes of Oncologist Burnout
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Outlining Strategies for Effectively Implementing Integrative Oncology Care
Navigating the Difficulties of Nutrition During Cancer Care as a Nurse
Navigating the Difficulties of Nutrition During Cancer Care as a Nurse
Genetic Counseling Referrals Rely on Genetic Report Examinations
Genetic Counseling Referrals Rely on Genetic Report Examinations
CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETs
CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETs
Related Content
Advertisement

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.

Related Content
Oncology Journal
|
Oncology
Advertisement

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.

Advertisement
Advertisement
Advertisement
Advertisement
x
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.